Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Shares Outstanding (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Shares Outstanding for 15 consecutive years, with $100.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding rose 0.7% year-over-year to $100.1 million, compared with a TTM value of $100.1 million through Dec 2025, up 0.7%, and an annual FY2025 reading of $100.1 million, up 0.7% over the prior year.
  • Shares Outstanding was $100.1 million for Q4 2025 at Neurocrine Biosciences, roughly flat from $99.7 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $101.2 million in Q3 2024 and bottomed at $94.5 million in Q1 2021.
  • Average Shares Outstanding over 4 years is $98.4 million, with a median of $99.0 million recorded in 2025.
  • The sharpest move saw Shares Outstanding rose 3.38% in 2024, then decreased 1.88% in 2025.
  • Year by year, Shares Outstanding stood at $94.8 million in 2021, then increased by 4.11% to $98.7 million in 2023, then increased by 0.71% to $99.4 million in 2024, then grew by 0.7% to $100.1 million in 2025.
  • Business Quant data shows Shares Outstanding for NBIX at $100.1 million in Q4 2025, $99.7 million in Q3 2025, and $99.0 million in Q2 2025.